Along with the expanded manufacturing and automation efficiencies, another note is that in the July 16 PR, they announced they are bringing on additional trial sites. It won't just be MD Anderson.
I thought the same thing when I read this PR. It also seems unusual that an 8-k was filed for this. Maybe trying to drive home the fact of expanded manufacturing without invoking a negative response? Any thoughts, anyone?
Market Data 
Markets 
AI
